116 related articles for article (PubMed ID: 15590875)
1. Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes.
Dansereau RJ; Crail DJ
Ann Pharmacother; 2005 Jan; 39(1):63-7. PubMed ID: 15590875
[TBL] [Abstract][Full Text] [Related]
2. Compatibility of risedronate sodium tablets with food thickeners.
Dansereau RJ; Crail DJ
Am J Health Syst Pharm; 2008 Nov; 65(22):2133-6. PubMed ID: 18997142
[TBL] [Abstract][Full Text] [Related]
3. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
Walker AD; Adachi JD
Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
[TBL] [Abstract][Full Text] [Related]
4. Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
Perkins AC; Frier M; Blackshaw PE; Spiller RC; Fairbairn KJ; Dansereau RJ; Kinghorn T; San P; Hosking D
Int J Pharm; 2006 Mar; 311(1-2):20-5. PubMed ID: 16431045
[TBL] [Abstract][Full Text] [Related]
5. Warfarin bioavailability with feeding tubes and enteral formula.
Klang M; Graham D; McLymont V
JPEN J Parenter Enteral Nutr; 2010; 34(3):300-4. PubMed ID: 20467012
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding.
Rush SD; Vernak C; Zhao F
Int J Pharm Compd; 2017; 21(1):83-87. PubMed ID: 28346201
[TBL] [Abstract][Full Text] [Related]
7. Determination of the optimum solvent system for extraction of minoxidil from a tablet dosage form.
Plakogiannis FM; Mahzouf SZ; Babar A
Pharm Acta Helv; 1989; 64(12):348-50. PubMed ID: 2616584
[TBL] [Abstract][Full Text] [Related]
8. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation.
Garg A; Garg S; She RW
Burns; 2011 Nov; 37(7):1150-3. PubMed ID: 21764219
[TBL] [Abstract][Full Text] [Related]
9. Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability.
Hausman DS; Cambron RT; Sakr A
Int J Pharm; 2005 Aug; 299(1-2):19-33. PubMed ID: 15979262
[TBL] [Abstract][Full Text] [Related]
10. Stability of sulfadiazine oral liquids prepared from tablets and powder.
Pathmanathan U; Halgrain D; Chiadmi F; Schlatter J; Vermerie N
J Pharm Pharm Sci; 2004 Apr; 7(1):84-7. PubMed ID: 15144740
[TBL] [Abstract][Full Text] [Related]
11. Loss of carbamazepine suspension through nasogastric feeding tubes.
Clark-Schmidt AL; Garnett WR; Lowe DR; Karnes HT
Am J Hosp Pharm; 1990 Sep; 47(9):2034-7. PubMed ID: 2121028
[TBL] [Abstract][Full Text] [Related]
12. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
Lam MS
Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
[TBL] [Abstract][Full Text] [Related]
13. Drug administration through feeding tubes; an integrated qualification program.
Martins Gonzaga do Nascimento M; Max Moreira Reis A; Yeznach Wick J; Queiroz Ribeiro A
Nutr Hosp; 2012; 27(4):1309-13. PubMed ID: 23165579
[TBL] [Abstract][Full Text] [Related]
14. Improving oral medicine administration in patients with swallowing problems and feeding tubes.
Hanssens Y; Woods D; Alsulaiti A; Adheir F; Al-Meer N; Obaidan N
Ann Pharmacother; 2006 Dec; 40(12):2142-7. PubMed ID: 17132805
[TBL] [Abstract][Full Text] [Related]
15. Potassium canrenoate compounding for administration via enteral feeding tubes: a physical and microbiological stability study.
Logrippo S; Sestili M; Ganzetti R; Bonacucina G; Marziali A; Fattoretti P; Busco S; Caraffa A; Polidori C; Palmieri GF
Eur J Hosp Pharm; 2018 Oct; 25(e2):e120-e125. PubMed ID: 31157081
[TBL] [Abstract][Full Text] [Related]
16. Development of an oral rutin nanocrystal formulation.
Mauludin R; Müller RH; Keck CM
Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
[TBL] [Abstract][Full Text] [Related]
17. [Study on dissolution in vitro of Zhike Pingchuan sustained-release tablets].
Li X; Feng Z; Huo W; Li Y; Wang B; Zhu S
Zhongguo Zhong Yao Za Zhi; 2009 May; 34(10):1216-9. PubMed ID: 19673379
[TBL] [Abstract][Full Text] [Related]
18. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
Glass BD; Haywood A
J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
[TBL] [Abstract][Full Text] [Related]
19. Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.
Dissette V; Bozzi P; Bignozzi CA; Dalpiaz A; Ferraro L; Beggiato S; Leo E; Vighi E; Pasti L
Eur J Pharm Sci; 2010 Oct; 41(2):328-36. PubMed ID: 20619342
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
